Drug Trial Radar · NCT05363280
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Nov 1, 2022
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Advenchen Pharmaceuticals, LLC.Industry
- Sponsor type
- Industry
- First posted
- May 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients who need ≥2nd line treatment .
Conditions
- Small Cell Lung Cancer
- Renal Cell Carcinoma (RCC)
- Non-Small Cell Lung
Interventions
AL8326 40 mgDrug
Taken AL3826 at 40mg QD orally
AL8326 60 mgDrug
Taken AL3826 at 60mg QD orally
AL8326 80 mg--stoppedDrug
Taken AL3826 at 80 mg QD orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Optimal biological dose ( OBD )Time frame: 12 months
- Objective Response Rates (ORR)Time frame: 12 month
- ORR evaluation for NSCLC and RCCTime frame: 24 month
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Cleveland Clinic Florida
Weston, Florida · Withdrawn
Northwestern University
Chicago, Illinois · Completed
Siteman Cancer Center, Washington University
St Louis, Missouri · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Universitario Ramón Y Cajal
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.